BackNAYA Biosciences Common Stock Overview

NAYA Biosciences Common Stock Total Current Liabilities

NAYA Biosciences Common Stock's total current liabilities is $6.4B.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$6.36B
66.05% YoYΔ $-12.36B vs prior year quarter

Peer average

Loading

NAYA Biosciences Common Stock Total Current Liabilities History

Loading

NAYA Biosciences Common Stock vs. peers: Total Current Liabilities Comparison

Loading

NAYA Biosciences Common Stock Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NAYA Biosciences Common Stock (IVF) FAQ

As of the most recent data (March 2026), IVF shows a total current liabilities of $6.4B. That compares with $19B in the prior-year period — down 66.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IVF's total current liabilities is now $6.4B (was $19B) — a 66.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NAYA Biosciences Common Stock is outperforming or lagging.

Tracking IVF's total current liabilities over time shows whether NAYA Biosciences Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $6.4B That compares with $19B in the prior-year period — down 66.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has NAYA Biosciences Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $6.4B) with ownership activity and broader fundamentals.

NAYA Biosciences Common Stock's total current liabilities is $6.4B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.